Home/ Stocks/ INMB

INmune Bio Inc. Common stock

INMB XNAS

$1.18 -0.05 (-4.02%) ▼ 15-min delayed

Open

$1.21

High

$1.22

Low

$1.16

Volume

272.5K

Market Cap

$32.97M

About INmune Bio Inc. Common stock

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-6,472,000	$-0.24
Q2 2025	$0	$-24,458,000	$-1.05
Q1 2025	$50.0K	$-9,739,000	$-0.43
FY 2024	$14.0K	$-42,082,000	$-2.11

Related Market News

No specific coverage for INMB yet. Check out our latest market news or earnings calendar.

Get INMB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on INmune Bio Inc. Common stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.